Mettler-Toledo International Inc. (0K10.L)
USD 1073.26
(8.25%)
USD 1073.26
(8.25%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.35 Billion USD | -3.92% |
| 2022 | 3.49 Billion USD | 4.98% |
| 2021 | 3.32 Billion USD | 18.2% |
| 2020 | 2.81 Billion USD | 0.9% |
| 2019 | 2.78 Billion USD | 6.51% |
| 2018 | 2.61 Billion USD | 2.71% |
| 2017 | 2.54 Billion USD | 17.68% |
| 2016 | 2.16 Billion USD | 10.59% |
| 2015 | 1.95 Billion USD | -2.48% |
| 2014 | 2 Billion USD | -6.68% |
| 2013 | 2.15 Billion USD | 6.45% |
| 2012 | 2.02 Billion USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 3.28 Billion USD | -2.16% |
| 2024 Q2 | 3.24 Billion USD | -1.03% |
| 2023 FY | 3.35 Billion USD | -3.92% |
| 2023 Q4 | 3.35 Billion USD | 2.03% |
| 2023 Q1 | 3.4 Billion USD | -2.36% |
| 2023 Q2 | 3.37 Billion USD | -1.16% |
| 2023 Q3 | 3.28 Billion USD | -2.42% |
| 2022 Q1 | 3.35 Billion USD | 0.88% |
| 2022 Q4 | 3.49 Billion USD | 6.01% |
| 2022 FY | 3.49 Billion USD | 4.98% |
| 2022 Q2 | 3.33 Billion USD | -0.59% |
| 2022 Q3 | 3.29 Billion USD | -1.26% |
| 2021 Q3 | 3.2 Billion USD | 2.04% |
| 2021 FY | 3.32 Billion USD | 18.2% |
| 2021 Q1 | 3.02 Billion USD | 7.6% |
| 2021 Q2 | 3.14 Billion USD | 3.78% |
| 2021 Q4 | 3.32 Billion USD | 3.73% |
| 2020 Q3 | 2.76 Billion USD | 3.24% |
| 2020 Q2 | 2.67 Billion USD | -7.14% |
| 2020 Q1 | 2.88 Billion USD | 3.46% |
| 2020 FY | 2.81 Billion USD | 0.9% |
| 2020 Q4 | 2.81 Billion USD | 1.74% |
| 2019 FY | 2.78 Billion USD | 6.51% |
| 2019 Q4 | 2.78 Billion USD | 5.82% |
| 2019 Q3 | 2.63 Billion USD | -0.94% |
| 2019 Q2 | 2.66 Billion USD | 0.92% |
| 2019 Q1 | 2.63 Billion USD | 0.68% |
| 2018 Q2 | 2.55 Billion USD | 1.84% |
| 2018 Q1 | 2.51 Billion USD | -1.49% |
| 2018 FY | 2.61 Billion USD | 2.71% |
| 2018 Q4 | 2.61 Billion USD | 2.39% |
| 2018 Q3 | 2.55 Billion USD | -0.02% |
| 2017 Q2 | 2.24 Billion USD | 2.01% |
| 2017 Q4 | 2.54 Billion USD | 2.11% |
| 2017 FY | 2.54 Billion USD | 17.68% |
| 2017 Q1 | 2.2 Billion USD | 1.71% |
| 2017 Q3 | 2.49 Billion USD | 11.09% |
| 2016 FY | 2.16 Billion USD | 10.59% |
| 2016 Q3 | 2.22 Billion USD | 7.72% |
| 2016 Q1 | 2.03 Billion USD | 3.88% |
| 2016 Q4 | 2.16 Billion USD | -2.44% |
| 2016 Q2 | 2.06 Billion USD | 1.3% |
| 2015 Q3 | 2.05 Billion USD | -2.07% |
| 2015 FY | 1.95 Billion USD | -2.48% |
| 2015 Q4 | 1.95 Billion USD | -4.59% |
| 2015 Q2 | 2.09 Billion USD | 6.14% |
| 2015 Q1 | 1.97 Billion USD | -1.66% |
| 2014 Q1 | 2.13 Billion USD | -0.82% |
| 2014 Q2 | 2.14 Billion USD | 0.39% |
| 2014 Q3 | 2.1 Billion USD | -1.68% |
| 2014 Q4 | 2 Billion USD | -4.67% |
| 2014 FY | 2 Billion USD | -6.68% |
| 2013 Q4 | 2.15 Billion USD | 0.41% |
| 2013 Q2 | 2.13 Billion USD | 3.03% |
| 2013 Q3 | 2.14 Billion USD | 0.5% |
| 2013 Q1 | 2.07 Billion USD | 2.39% |
| 2013 FY | 2.15 Billion USD | 6.45% |
| 2012 FY | 2.02 Billion USD | 0.0% |
| 2012 Q4 | 2.02 Billion USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 96.601% |
| Dynavax Technologies Corporation | 997.09 Million USD | -236.533% |
| Illumina, Inc. | 10.11 Billion USD | 66.813% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 87.423% |
| Biogen Inc. | 26.84 Billion USD | 87.5% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -330.006% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | -2.787% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -138.155% |
| Waters Corporation | 4.62 Billion USD | 27.477% |
| Perrigo Company plc | 10.8 Billion USD | 68.956% |
| uniQure N.V. | 831.68 Million USD | -303.463% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -258.072% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -331.372% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -1927.477% |
| bluebird bio, Inc. | 619.16 Million USD | -441.952% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -2566.44% |
| Imunon, Inc. | 21.91 Million USD | -15209.538% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -179.933% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | -3.203% |
| Nektar Therapeutics | 398.03 Million USD | -743.034% |
| Editas Medicine, Inc. | 499.15 Million USD | -572.25% |
| Verastem, Inc. | 149.71 Million USD | -2141.25% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 95.859% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -11768.663% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -1408.074% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -5008.167% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 50.954% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -1929.733% |
| Evolus, Inc. | 188.99 Million USD | -1675.445% |
| Adicet Bio, Inc. | 207.29 Million USD | -1518.734% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -1599.833% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 89.856% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -1530.525% |
| FibroGen, Inc. | 423.52 Million USD | -692.285% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 68.823% |
| OPKO Health, Inc. | 2.01 Billion USD | -66.802% |
| Homology Medicines, Inc. | 47.05 Million USD | -7030.831% |
| Geron Corporation | 394.07 Million USD | -751.499% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 12.385% |
| Exelixis, Inc. | 2.94 Billion USD | -14.043% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -810.623% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -2073.484% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -157.926% |
| Zoetis Inc. | 14.28 Billion USD | 76.512% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -470.444% |
| Abeona Therapeutics Inc. | 64 Million USD | -5142.891% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 85.237% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -5897.525% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | -12.223% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -439.898% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -93.597% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -219.805% |
| Insmed Incorporated | 1.32 Billion USD | -152.328% |
| TG Therapeutics, Inc. | 329.58 Million USD | -918.109% |
| Incyte Corporation | 6.78 Billion USD | 50.523% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | -82.874% |